Lineage Therap (LCTX) Stock Statistics & Valuation Metrics

Lineage Therap has a market cap or net worth of $460.81M. The enterprise value is $387.73M.

Lineage Therap has 249,087,520 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lineage Therap’s return on equity (ROE) is -1.43 and return on invested capital (ROIC) is -19.75%.

The current PE Ratio of Lineage Therap is ―. Lineage Therap’s PEG ratio is -0.03.

In the last 12 months, Lineage Therap had revenue of 14.56M and earned -63.53M in profits. Earnings per share was -0.28.

In the last 12 months, operating cash flow was -18.92M and capital expenditures -234.00K, giving a free cash flow of -19.15M billion.

Lineage Therap pays an annual dividend of ―, resulting in a dividend yield of ―

Lineage Therap upcoming earnings date is May 7, 2026, After Close (Confirmed).

Lineage Therap as a current ratio of 5.20, with Debt / Equity ratio of 5.43%

In the past 12 months, Lineage Therap has paid -5.11M in taxes.

Lineage Therap EV to EBITDA ratio is -9.45, with an EV/FCF ratio of -18.28.

Lineage Therap has $55.78M in cash and marketable securities with $2.42M in debt, giving a net cash position of $53.36M billion.

Gross margin is 98.96%, with operating margin of -149.62%, and net profit margin of -436.47%.

The average price target for Lineage Therap is $9.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy